Skip to main content

Table 2 Comparison of clinical outcomes at 2 years

From: Outcomes between prediabetes and type 2 diabetes mellitus in older adults with acute myocardial infarction in the era of newer-generation drug-eluting stents: a retrospective observational study

Outcomes

Group A

Normoglycemia

(n = 1193)

Group B

Prediabetes

(n = 1696)

Log-Rank

Unadjusted

Adjusteda

HR (95% CI)

p value

HR (95% CI)

p value

MACE

85 (8.0)

163 (10.2)

0.038

1.319 (1.015–1.714)

0.039

1.373 (1.051–1.795)

0.020

All-cause death

49 (4.4)

90 (5.6)

0.191

1.260 (0.890–1.785)

0.192

1.364 (0.952–1.955)

0.091

Cardiac death

37 (3.3)

68 (4.2)

0.240

1.270 (0.851–1.896)

0.242

1.285 (0.847–1.949)

0.238

Re-MI

19 (2.0)

34 (2.2)

0.493

1.217 (0.694–2.133)

0.494

1.262 (0.708–2.247)

0.430

All-cause death or MI

63 (5.9)

124 (7.7)

0.050

1.352 (0.998–1.831)

0.051

1.436 (1.052–1.961)

0.022

Any repeat revascularization

26 (2.7)

53 (3.5)

0.190

1.367 (0.855–2.186)

0.191

1.381 (0.857–2.225)

0.184

Stent thrombosis (probable or definite)

3 (0.3)

9 (0.5)

0.250

2.114 (0.572–7.809)

0.261

2.257 (0.600–8.487)

0.228

Outcomes

Group A

Normoglycemia

(n = 1193)

Group C

Diabetes

(n = 2603)

Log-Rank

Unadjusted

Adjusteda

HR (95% CI)

p value

HR (95% CI)

p value

MACE

85 (8.0)

306 (12.5)

< 0.001

1.620 (1.274–2.061)

< 0.001

1.479 (1.149–1.904)

0.002

All-cause death

49 (4.4)

186 (7.5)

0.001

1.710 (1.248–2.342)

0.001

1.666 (1.193–2.327)

0.003

Cardiac death

37 (3.3)

130 (5.2)

0.012

1.592 (1.105–2.293)

0.013

1.474 (0.998–2.178)

0.051

Re-MI

19 (2.0)

66 (2.9)

0.091

1.547 (0.929–2.577)

0.094

1.330 (0.781–2.265)

0.294

All-cause death or MI

63 (5.9)

243 (9.9)

< 0.001

1.740 (1.319–2.296)

< 0.001

1.647 (1.231–2.205)

0.001

Any repeat revascularization

26 (2.7)

94 (4.2)

0.031

1.605 (1.040–2.479)

0.033

1.269 (0.805–2.002)

0.305

Stent thrombosis (probable or definite)

3 (0.3)

20 (0.8)

0.057

3.063 (0.910–10.31)

0.071

2.185 (0.618–7.727)

0.225

Outcomes

Group B

Prediabetes

(n = 1696)

Group C

Diabetes

(n = 2603)

Log-Rank

Unadjusted

Adjusteda

HR (95% CI)

p value

HR (95% CI)

p value

MACE

163 (10.2)

306 (12.5)

0.032

1.231 (1.018–1.488)

0.032

1.112 (0.911–1.359)

0.297

All-cause death

90 (5.6)

186 (7.5)

0.017

1.359 (1.056–1.747)

0.017

1.232 (0.945–1.608)

0.124

Cardiac death

68 (4.2)

130 (5.2)

0.129

1.254 (0.935–1.682)

0.130

1.108 (0.813–1.510)

0.518

Re-MI

34 (2.2)

66 (2.9)

0.244

1.278 (0.845–1.933)

0.245

1.127 (0.730–1.737)

0.590

All-cause death or MI

124 (7.7)

243 (9.9)

0.021

1.288 (1.038–1.599)

0.022

1.170 (0.932–1.470)

0.176

Any repeat revascularization

53 (3.5)

94 (4.2)

0.351

1.174 (0.838–1.644)

0.351

1.018 (0.716–1.449)

0.920

Stent thrombosis (probable or definite)

9 (0.5)

20 (0.8)

0.353

1.449 (0.660–3.181)

0.356

1.219 (0.535–2.778)

0.637

  1. aAdjusted by age, male, LVEF, SBP, STEMI, cardiogenic shock, CPR on admission, Killip class III/IV, dyslipidemia, previous MI and CVA, peak CK-MB, NT-ProBNP, serum creatinine, eGFR, total cholesterol, HDL-cholesterol, LDL-cholesterol, clopidogrel, ticagrelor, BB, ACEI, ARB, lipid lowering agents, single-vessel disease, ≥ three-vessel disease ACC/AHA type B2/C lesions, pre-PCI TIMI flow grade 2/3, and number of stent
  2. MACE major adverse cardiac events, Re-MI recurrent myocardial infarction, LVEF left ventricular ejection fraction, SBP systolic blood pressure, STEMI ST-segment elevation myocardial infarction, CPR cardiopulmonary resuscitation, MI myocardial infarction, CVA cerebrovascular events, CK-MB creatine kinase myocardial band, NT-ProBNP N-terminal pro-brain natriuretic peptide, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, LDL low-density lipoprotein, BB beta-blocker, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, PCI percutaneous coronary intervention, TIMI Thrombolysis In Myocardial Infarction
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us